Reflux Disease clinical trials

Explore recruiting reflux disease clinical trials.

Recruiting reflux disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Reflux Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A placebo-controlled trial with prucalopride for the treatment of typical reflux symptoms in patients with gastro-esophageal reflux disease with incomplete proton pump inhibitor response.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Reflux Disease trials by city

Reflux Disease in Toronto Reflux Disease in Vancouver Reflux Disease in Montreal Reflux Disease in Calgary Reflux Disease in Edmonton Reflux Disease in Ottawa Reflux Disease in Winnipeg Reflux Disease in Quebec City Reflux Disease in Hamilton Reflux Disease in Kitchener Reflux Disease in London Reflux Disease in Halifax Reflux Disease in New York Reflux Disease in Los Angeles Reflux Disease in Chicago Reflux Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease